CN108635361B - 一种具有抗炎活性的琼花提取物及其活性成分和分离方法 - Google Patents
一种具有抗炎活性的琼花提取物及其活性成分和分离方法 Download PDFInfo
- Publication number
- CN108635361B CN108635361B CN201810376906.1A CN201810376906A CN108635361B CN 108635361 B CN108635361 B CN 108635361B CN 201810376906 A CN201810376906 A CN 201810376906A CN 108635361 B CN108635361 B CN 108635361B
- Authority
- CN
- China
- Prior art keywords
- extract
- fraction
- compound
- mobile phase
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims abstract description 40
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 23
- 238000000926 separation method Methods 0.000 title claims abstract description 10
- 239000004480 active ingredient Substances 0.000 title claims description 13
- 241000628997 Flos Species 0.000 title description 2
- -1 3-hydroxy-4- (6-benzoyl- β -D-glucopyranosyl) benzyl Chemical group 0.000 claims abstract description 25
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Natural products C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000000605 extraction Methods 0.000 claims abstract description 16
- 229960002903 benzyl benzoate Drugs 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 45
- 229920001817 Agar Polymers 0.000 claims description 24
- 239000008272 agar Substances 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000004440 column chromatography Methods 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 229940125904 compound 1 Drugs 0.000 claims description 9
- 229940125782 compound 2 Drugs 0.000 claims description 9
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 claims description 9
- 239000002024 ethyl acetate extract Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 210000003918 fraction a Anatomy 0.000 claims description 6
- 238000011068 loading method Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- QCLMZTCDRVMSHA-UHFFFAOYSA-N benzyl 3-hydroxybenzoate Natural products OC1=CC=CC(C(=O)OCC=2C=CC=CC=2)=C1 QCLMZTCDRVMSHA-UHFFFAOYSA-N 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000010898 silica gel chromatography Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 241000222518 Agaricus Species 0.000 abstract description 9
- 238000010992 reflux Methods 0.000 abstract description 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 description 25
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000003810 ethyl acetate extraction Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 235000013250 Viburnum opulus var sargentii Nutrition 0.000 description 2
- 240000004861 Viburnum opulus var. sargentii Species 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical class C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 241001180472 Iris japonica Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 241000208832 Viburnum Species 0.000 description 1
- 241000038334 Viburnum macrocephalum Species 0.000 description 1
- 235000019013 Viburnum opulus Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 1
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930182487 phenolic glycoside Natural products 0.000 description 1
- 150000007950 phenolic glycosides Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Substances [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有抗炎活性的琼花提取物及其活性成分和该活性成分的提取分离方法,以及该活性成分在抗炎方面的应用,所述琼花提取物是以体积百分数为70%至95%的乙醇水溶液为提取剂对琼花地上干燥部分进行回流提取,所得提取液即为所述琼花提取物;通过对所述琼花提取物进行处理,提取分离出两种抗炎活性成分,即3‑羟基‑4‑(6‑苯甲酰基‑β‑D‑吡喃葡萄糖基)苯甲酸苯甲酯和4‑羟基‑3‑(6‑肉桂酰基‑β‑D‑吡喃葡萄糖基)苯甲酸苯甲酯,上述琼花提取物和两种化合物均表现出明显的抗炎作用,能够在制药、食品及保健品领域应用。
Description
技术领域
本发明涉及一种具有抗炎活性的琼花提取物及其活性成分和分离方法,属于琼花抗炎活性成分提取分离技术领域。
背景技术
琼花(拉丁学名:Viburnum macrocephalum Fort.f.keteleeri)为荚蒾属植物。琼花又称聚八仙、蝴蝶花,属于绣球荚蒾的变种,为我国特有的名贵花木。琼花是扬州市花和昆山三宝之一,为忍冬科半常绿灌木。春季其花大如盘、洁白如玉;秋季果实累累、红绿相间,是极具观赏价值的园林植物。近年来以扬州瘦西湖、昆山亭林园为源头,琼花得以大规模繁殖,已经成为道路绿化、公园景观以及小区绿化的特色树种。在民间,琼花常以枝、叶、果入药,具有通经活络、解毒止痒之功效,一般春夏采摘,晒干可用。茎煎水可治风湿疥癣,皮肤痒痛,内服外用均可;花泡酒,可治跌打损伤。
国内外对其药学应用的物质基础研究尚不多见,截至目前,文献报道的仅见从琼花中分离得到的8个黄酮类化合物。
发明内容
发明目的:针对上述技术问题,本发明提供了一种具有抗炎活性的琼花提取物及其活性成分和分离方法,该琼花提取物以及所得两种活性成分,均可以作为炎症治疗药物,以及炎症为并发症的各种重大疾病的辅助治疗药物、食品及保健品。
技术方案:为了达到上述发明目的,本发明所采用的技术方案如下:
一种具有抗炎活性的琼花提取物,以体积百分数为70%至95%的乙醇水溶液为提取剂对琼花地上干燥部分进行回流提取,所得提取液即为所述琼花提取物。
上述回流提取时,料液比为1:(4-6),提取次数为2-4次,每次提取时间为1-3h。
一种所述琼花提取物中的抗炎活性成分,其为3-羟基苯甲酸苯甲酯类化合物,化学结构式如下所示:
化合物1:3-羟基-4-(6-苯甲酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯,分子式为C27H26O10,分子量为510.1526。
另一种所述琼花提取物中的抗炎活性成分,其为4-羟基苯甲酸苯甲酯类化合物,化学结构式如下所示:
化合物2:4-羟基-3-(6-肉桂酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯,分子式为C29H28O10,分子量为536.1682。
本发明上述提取物和化合物均表现出明显的抗炎作用。作为植物提取物,可作为抗炎药物应用于炎症治疗及炎症为并发症的各种重大疾病的辅助治疗药物、食品及保健品领域。本发现丰富了对琼花中次生代谢产物的认识,为琼花在药品、食品及保健品领域应用的开发、合理应用及深入研究提供科学依据。
上述3-羟基苯甲酸苯甲酯类化合物和4-羟基苯甲酸苯甲酯类化合物的提取方法,包括以下步骤:
(1)采用乙醇的水溶液对琼花地上部位进行回流提取,通过减压回收溶剂,对提取液进行浓缩干燥,取得浸膏,将浸膏溶解于蒸馏水中,采用乙酸乙酯进行萃取,取得乙酸乙酯萃取液,此萃取液进行减压浓缩后,获得乙酸乙酯萃取浸膏;
(2)乙酸乙酯萃取浸膏上样于MCI微孔树脂色谱柱,以体积百分数为80%至90%的甲醇水溶液为流动相,进行洗脱,收集此流动相的洗脱物,减压浓缩得到流分A;
(3)将流分A上样于硅胶柱色谱,先后以体积比为100:4和100:8的氯仿和甲醇混合液为流动相,进行洗脱,分别收集洗脱物,得到两个流分,流分A-1和流分A-2;
(4)流分A-2经Sephadex LH-20柱色谱进行分离,以体积百分数为55%至60%的甲醇水溶液为流动相,经Sephadex LH-20柱色谱进行梯度洗脱,收集此流动相的洗脱物,减压浓缩得流分A-2-1;
(5)流分A-2-1经ODS柱色谱进行分离,以体积百分数为40%至65%的甲醇水溶液为流动相进行梯度洗脱,收集此流动相的洗脱物,减压浓缩取得流分A-2-1-1和流分A-2-1-2;
流分A-2-1-1经鉴定,即为所述化合物1:3-羟基-4-(6-苯甲酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯。
流分A-2-1-2经鉴定,即为所述化合物2:4-羟基-3-(6-肉桂酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯。
所述步骤(1)中浓缩干燥的温度为40℃。
步骤(2)中所述的乙酸乙酯萃取浸膏先用体积百分数为80%至90%的甲醇水溶液溶解,然后再上样。
本发明的提取分离工艺特点如下:采用一定浓度的乙醇-水溶液对药材进行提取---乙酸乙酯萃取结合MCI微孔树脂富集目标化合物---硅胶、Sephadex LH-20和ODS柱色谱法进行细化分离。通过这一流程,能够最大可能富集琼花中连接单糖的酚苷类次生代谢产物。通过乙酸乙酯萃取除去多糖等强极性化合物,通过MCI微孔树脂去除脂肪酸及叶绿素等小极性化合物,最后依据化合物的结构和极性的差异,通过硅胶、Sephadex LH-20和ODS柱色谱方法进一步将3-羟基-4-(6-苯甲酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯和4-羟基-3-(6-肉桂酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯纯化出来。
本发明还提供了一种组合物,该组合物包含所述琼花提取物、所述3-羟基苯甲酸苯甲酯类化合物和/或所述4-羟基苯甲酸苯甲酯类化合物,以及药学、食品及保健品可接受的载体或赋形剂。
所述药学、食品及保健品可接受的载体或赋形剂选自稀释剂、分散剂、助悬剂、表面活性剂、等渗剂、增稠剂、乳化剂、防腐剂、粘合剂、润滑剂、稳定剂、水合剂、乳化加速剂、缓冲剂、吸收剂、着色剂、香味剂、甜味剂、离子交换剂、脱模剂、涂布剂、矫味剂、和抗氧化剂等。
本发明最后提供了所述琼花提取物、所述3-羟基苯甲酸苯甲酯类化合物或所述4-羟基苯甲酸苯甲酯类化合物在制备抗炎药物、食品或保健品中的应用。其作为抗炎药物、食品或保健品,可以应用于炎症治疗,以及炎症为并发症的各种重大疾病的辅助治疗。
技术效果:相对于现有技术,本发明首次提出了从琼花乙醇提取物的乙酸乙酯萃取部分分离得到新化合物,并且通过乙醇-水溶液对药材进行提取---乙酸乙酯萃取结合MCI微孔树脂富集目标化合物---硅胶、Sephadex LH-20和ODS柱色谱法进行细化分离,从而能够最大可能富集该化合物;所得化合物表现出明显的抗炎作用,可用于炎症治疗及炎症为并发症的各种重大疾病的辅助治疗药物、食品及保健品。
附图说明
图1为本发明化合物的正离子高分辨质谱图,其中A为化合物1,B为化合物2;
图2为本发明化合物的红外图,其中A为化合物1,B为化合物2;
图3为本发明化合物的紫外图,其中A为化合物1,B为化合物2;
图4为本发明化合物的HSQC图(1H的异核单量子相干相关谱,即1H核与其直接相连的13C相关联),其中A为化合物1,B为化合物2;
图5为本发明化合物的HMBC图[1H的异核多键相关谱。突出表现1H核与相隔2个键(2JCH)和相隔3个键(3JCH)的13C相关联],其中A为化合物1,B为化合物2。
具体实施方式
下面通过具体实施例对本发明所述的技术方案给予进一步详细的说明,但有必要指出以下实施例只用于对发明内容的描述,并不构成对本发明保护范围的限制。
实施例
一.使用的仪器与材料:
1.Bruker AVANCE-600型核磁共振波谱仪(德国),Bruker MaXis超高分辨飞行时间质谱仪(德国)。Heal Force HF90CO2培养箱(中国济南);Thermo Multiskan GO全波长酶标仪(美国)
2.MCI微孔树脂:由日本三菱公司生产;Sephadex LH-20:由美国GE公司生产销售;柱层析硅胶:200-300目,由中国青岛海洋化工公司生产销售;ODS:由日本YMC生产。
高效硅胶板GF254:由中国青岛海洋化工公司生产销售;色谱试剂均为分析纯。
3.琼花采自江苏省扬州市,并由扬州大学生物科学与技术学院淮虎银教授鉴定为琼花(Viburnum macrocephalum Fort.f.keteleeri),留样标本(20131005)存放在扬州大学生物科学与技术学院。
二.琼花提取物制备:
1.取1.0kg琼花干燥地上部分,以体积百分数为70%的乙醇为提取溶剂,料液比为1:5,回流提取三次,每次2h。合并提取液,即得所述琼花提取物;
2.取1.0kg琼花干燥地上部分,以体积百分数为85%的乙醇为提取溶剂,料液比为1:4,回流提取4次,每次1h。合并提取液,即得所述琼花提取物;
3.取1.0kg琼花干燥地上部分,以体积百分数为95%的乙醇为提取溶剂,料液比为1:5,回流提取2次,每次3h。合并提取液,即得所述琼花提取物;
三、抗炎活性成分分离:
1、将上述琼花提取物制备项所得琼花提取物在40℃下减压浓缩,得约250g浸膏。将250g浸膏溶解于1L蒸馏水后,用等体积乙酸乙酯进行萃取,取得乙酸乙酯层萃取液。萃取液减压浓缩后得到浸膏35g。
2.将35g乙酸乙酯萃取浸膏溶于300mL体积百分数为80%至90%的甲醇水溶液中,300mL乙酸乙酯萃取物溶液上样于MCI微孔树脂色谱柱,以体积百分数为80%至90%的甲醇水溶液300mL作为流动相进行洗脱,收集洗脱液后减压浓缩得29g流分A。
3.取流分A,将29g浸膏加入58g柱层析硅胶拌样,经100至200g硅胶柱色谱分离。其中色谱分离的流动相依次采用体积比为100:4和100:8的氯仿和甲醇混合液。洗脱液经薄层色谱分析。最终,洗脱液分为2个流分:流分A-1和流分A-2。
4.将流分A-2减压浓缩干燥,取4.5g于体积百分数为55%至60%的甲醇水溶液溶解,经200g Sephadex LH-20柱色谱分离,以体积百分数为55%至60%的甲醇水溶液为流动相,取得流分A-2-1;
5.将流分A-2-1减压浓缩干燥后,取31mg,经ODS柱色谱分离,以体积百分数为40%至65%的甲醇水溶液为流动相,取得流分A-2-1-1和流分A-2-1-2;
6.对化合物3-羟基-4-(6-苯甲酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯进行鉴定:
流分A-2-1-1经鉴定为化合物3-羟基-4-(6-苯甲酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯,为白色无定形粉末(甲醇)。三氯化铁-铁***反应呈阳性,Molisch反应阳性,酸水解检出葡萄糖。HR-ESI-MS m/z:533.1429([M+Na]+,C27H26O10Na,Calcd 533.1418)。UV(MeOH)λmax nm(logε)203(4.53),210(4.57),312(1.26)。IR(KBr)vmax 3382,2919,1710,1603,1498,1452,1383.8,1278,1211,1070,1027,967,908,810,783,714,624,588,463cm-1。并利用一维和二维NMR、质谱等技术鉴定其结构。
氢谱和碳谱数据如下:
1H-NMR(600MHz,DMSO-d6),δ:7.94(2H,m,H-2”',6”'),7.68(1H,m,H-4”'),7.53(2H,m,H-3”',5”'),7.45(2H,m,H-2',6'),7.38(2H,m,H-3',5'),7.33(1H,m,H-4'),7.10(1H,d,J=8.8Hz,H-5),7.02(1H,d,J=3.2Hz,H-2),6.75(1H,dd,J=3.2,8.8Hz,H-6),5.24(1H,d,J=12.7Hz,H-7'a),5.22(1H,d,J=12.7Hz,H-7'b),4.82(1H,d,J=7.4Hz,H-1”),4.57(1H,dd,J=2.2,11.9Hz,H-6”a),4.26(1H,dd,J=7.1,11.9Hz,H-6”b),3.70(1H,m,H-5”),3.31(2H,overlap,H-2”,3”),3.28(1H,m,H-4”)。13C-NMR(150MHz,DMSO-d6),δ:165.6(C-7),165.5(C-7”'),152.0(C-3),148.7(C-4),136.1(C-1'),133.3(C-4”'),129.6(C-1”'),129.1(C-2”',6”'),128.6(C-3”',5”'),128.3(C-3',5'),127.9(C-2',4',6'),122.4(C-1),119.8(C-6),118.9(C-5),116.0(C-2),102.0(C-1”),76.3(C-3”),73.7(C-5”),73.3(C-2”),70.0(C-4”),66.1(C-7'),64.1(C-6”)。
从图1A可见:化合物3-羟基-4-(6-苯甲酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯的[M+Na]+(C27H26O10Na)的分子量为533.1429。
从图2A可见:特征区内v C=C 1603cm-1及指纹区γ=CH 714cm-1为取代苯的特征吸收峰;v C=O 1710cm-1、v as C―O―C 1278cm-1、v s C―O―C 1027cm-1为酯的一组相关峰;v OH3382cm-1、v=C―O 1211cm-1及v C―O 1070cm-1表明化合物中存在酚和醇结构。
从图3A可见:在312nm处吸收,表明该化合物含有苯结构,且存在与苯环共轭的不饱和基团。
从图4A可见:δ:116.0(C-2)与7.02(1H,d,J=3.2Hz,H-2),118.9(C-5)与7.10(1H,d,J=8.8Hz,H-5),119.8(C-6)与6.75(1H,dd,J=8.8,3.2Hz,H-6),127.9(C-2')与7.45(1H,m,H-2'),128.3(C-3')与7.38(1H,m,H-3'),127.9(C-4')与7.33(1H,m,H-4'),128.3(C-5')与7.38(1H,m,H-5'),127.9(C-6')与7.45(1H,m,H-6'),66.1(C-7')与5.24(1H,d,J=12.7Hz,H-7'a)5.22(1H,d,J=12.7Hz,H-7'b),102.0(C-1”)与4.82(1H,d,J=7.4Hz,H-1”),73.3(C-2”)与3.31(1H,m,H-2”),76.3(C-3”)与3.31(1H,m,H-3”),70.0(C-4”)与3.28(1H,m,H-4”),73.7(C-5”)与3.70(1H,m,H-5”),64.1(C-6”)与4.57(1H,dd,J=11.9,2.2Hz,H-6”a)4.26(1H,dd,J=11.9,7.1Hz,H-6”b),129.1(C-2”')与7.94(1H,m,H-2”'),128.6(C-3”')与7.53(1H,m,H-3”'),133.3(C-4”')与7.68(1H,m,H-4”'),128.6(C-5”')与7.53(1H,m,H-5”'),129.1(C-6”')与7.94(1H,m,H-6”')分别相互关联,其结果与化合物3-羟基-4-(6-苯甲酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯的结构相一致。
从图5A可见:δ:127.9(C-2',C-6')与5.24(H-7')和5.22(H-7'),165.5(C-7”')与7.49(H-2”',6”'),165.6(C-7)与5.24(H-7')和5.22(H-7'),148.7(C-4)与4.82(H-1”),165.5(C-7”')与4.57(H-6”)和4.26(H-6”)分别相互关联,其结果与化合物3-羟基-4-(6-苯甲酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯的结构相一致。
通过以上鉴定,确定流分A-2-1-1为单体化合物,3-羟基-4-(6-苯甲酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯。
7.对化合物4-羟基-3-(6-肉桂酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯进行鉴定:
流分A-2-1-2经鉴定为化合物4-羟基-3-(6-肉桂酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯,为白色无定形粉末(甲醇)。三氯化铁-铁***反应呈阳性,Molisch反应阳性,酸水解检出葡萄糖。HR-ESI-MS m/z:559.1582([M+Na]+,C29H28O10Na,Calcd 559.1575)。UV(MeOH)λmax nm(logε)210(4.61),243(1.57),278(3.15)。IR(KBr)vmax 3422,2945,1688,1636,1488,1451,1385,1330,1284,1207,1076,1029,830,787,770,697,554cm-1。并利用一维和二维NMR、质谱等技术鉴定其结构。
氢谱和碳谱数据如下:
1H-NMR(600MHz,DMSO-d6),δ:7.69(2H,m,H-2”',6”'),7.61(1H,d,J=16.0Hz,H-7”'),7.45(3H,overlap,H-2',6',4”'),7.43(3H,overlap,H-2,3”',5”'),7.39(2H,m,H-3',5'),7.35(1H,m,H-4'),7.26(1H,dd,J=3.1,9.1Hz,H-6),6.88(1H,d,J=9.1Hz,H-5),6.62(1H,d,J=16.0Hz,H-8”'),5.32(1H,s,H-7'),4.79(1H,d,J=7.7Hz,H-1”),4.39(1H,dd,J=2.0,11.9Hz,H-6”a),4.21(1H,dd,J=6.6,11.9Hz,H-6”b)。13C-NMR(150MHz,DMSO-d6),δ:167.9(C-7),166.1(C-9”'),155.2(C-4),149.6(C-3),144.6(C-7”'),135.6(C-1'),134.0(C-1”'),130.5(C-4”'),129.0(C-3”',5”'),128.5(C-3',5'),128.4(C-2”',6”'),128.3(C-4'),127.9(C-2',6'),125.1(C-6),118.2(C-5),117.9(C-8”'),117.2(C-2),113.1(C-1),101.6(C-1”),76.1(C-3”),73.7(C-5”),73.1(C-2”),69.8(C-4”),66.6(C-7'),63.5(C-6”)。
从图1B可见:化合物4-羟基-3-(6-肉桂酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯的[M+Na]+(C29H28O10Na)的分子量为559.1582。
从图2B可见:特征区内v C=C 1636cm-1表明有双键存在;v C=O 1688cm-1、v as C―O―C1284cm-1、v s C―O―C 1029cm-1为酯的一组相关峰;v OH 3422cm-1、v=C―O 1207cm-1及v C―O1076cm-1表明化合物中存在酚、醇结构。
从图3B可见:在243nm、278nm处吸收,表明该化合物为芳香族化合物,且结构中存在含杂原子的不饱和基团。
从图4B可见:δ:117.2(C-2)与7.43(1H,overlap,H-2),118.2(C-5)与6.88(1H,d,J=9.1Hz,H-5),125.1(C-6)与7.26(1H,dd,J=3.1,9.1Hz,H-6),127.9(C-2')与7.45(1H,m,H-2'),128.5(C-3')与7.39(1H,m,H-3'),128.3(C-4')与7.35(1H,m,H-4'),128.5(C-5')与7.39(1H,m,H-5'),127.9(C-6')与7.45(1H,m,H-6'),66.61(C-7')与5.32(2H,s,H-7'),101.6(C-1”)与4.79(1H,d,J=7.7Hz,H-1”),73.1(C-2”)与3.24(1H,m,H-2”),76.1(C-3”)与3.30(1H,m,H-3”),69.8(C-4”)与3.24(1H,m,H-4”),73.7(C-5”)与3.62(1H,m,H-5”),63.5(C-6”)与4.39(1H,dd,J=2.0,11.9Hz,H-6”a)4.21(1H,dd,J=6.6,11.9Hz,H-6”b),128.4(C-2”')与7.69(1H,m,H-2”'),129.0(C-3”')与7.43(1H,m,H-3”'),130.5(C-4”')与7.45(1H,m,H-4”'),129.0(C-5”')与7.43(1H,m,H-5”'),128.4(C-6”')与7.69(1H,m,H-6”'),144.6(C-6”')与7.61(1H,d,J=16.0Hz,H-7”'),117.9(C-7”)与6.62(1H,d,J=16.0Hz,H-8”')分别相互关联,其结果与化合物4-羟基-3-(6-肉桂酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯的结构相一致。
从图5B可见:δ:149.6(C-3)与4.79(H-1”)和6.88(H-5),155.2(C-4)与7.43(H-2)和7.26(H-6),167.9(C-7)与5.32(H-7'),66.6(C-7')与7.45(H-2',6'),134.0(C-1”')与6.62(H-8”'),128.4(C-2”',6”')与7.61(H-7”'),166.1(C-9”')与4.39(H-6”a),4.21(H-6”b)和7.61(H-7”')分别相互关联,其结果与化合物4-羟基-3-(6-肉桂酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯的结构相一致。
通过以上鉴定,说明流分A-2-1-2为单体化合物,4-羟基-3-(6-肉桂酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯。
四、本发明琼花提取物和活性化合物的抗炎活性考察
本发明申请以抑制小鼠单核巨噬细胞NO生成率作为抗炎活性的检测指标。以LPS刺激小鼠单核巨噬细胞,使iNOS高表达,产生大量的NO,NO在液体培养基中迅速转变为亚硝酸盐,与Griess试剂反应后溶液呈红色,在540nm处有吸收。通过计算反应的亚硝酸盐的量来测定溶液中NO的量,进而得出药物对NO释放的影响。
首先取活力良好的RAW264.7细胞,将细胞浓度调节至5×105/ml,接种到96孔板上,每孔接种100μl,置于37℃、5%CO2培养箱中培养;用DMSO溶解供试样品,然后用培养液进行梯度稀释;每孔加入LPS(终浓度1μg/ml)和不同浓度的样品溶液,共100μl,置于37℃、5%CO2培养箱中培养24h;实验中设空白调零组、正常组(不加LPS、不加样品)、LPS模型组(不加样品)及阳性对照组,每个样品测定均平行重复三次;每孔取50μl培养液上清至另一96孔板中,室温下加入试剂盒中的Griess试剂I和Griess试剂II各50μl;室温下反应10min,在波长540nm处测定其OD值。绘制NaNO2标准曲线,根据标准曲线计算化合物对NO释放的抑制率。
琼花乙酸乙酯层两种新化合物对NO的抑制作用
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,作出的若干改进和润饰也应视为本发明的保护范围。
Claims (6)
2.权利要求1所述抗炎活性成分的提取分离方法,其特征在于,包括以下步骤:
(1)对所述琼花提取物进行浓缩干燥,取得浸膏,将浸膏溶解于蒸馏水中,采用乙酸乙酯进行萃取,取得乙酸乙酯萃取液,此萃取液进行减压浓缩后,获得乙酸乙酯萃取浸膏;
(2)乙酸乙酯萃取浸膏上样于MCI微孔树脂色谱柱,以体积百分数为80%至90%的甲醇水溶液为流动相,进行洗脱,收集此流动相的洗脱物,减压浓缩得到流分A;
(3)将流分A上样于硅胶柱色谱,先后以体积比为100:4和100:8的氯仿和甲醇混合液为流动相,进行洗脱,分别收集洗脱物,得到两个流分,流分A-1和流分A-2;
(4)流分A-2经Sephadex LH-20柱色谱进行分离,以体积百分数为55%至60%的甲醇水溶液为流动相,经Sephadex LH-20柱色谱进行梯度洗脱,收集此流动相的洗脱物,减压浓缩得流分A-2-1;
(5)流分A-2-1经ODS柱色谱进行分离,以体积百分数为40%至65%的甲醇水溶液为流动相进行梯度洗脱,收集此流动相的洗脱物,减压浓缩取得流分A-2-1-1和流分A-2-1-2;
流分A-2-1-1经鉴定,即为所述化合物1:3-羟基-4-(6-苯甲酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯;
流分A-2-1-2经鉴定,即为所述化合物2:4-羟基-3-(6-肉桂酰基-β-D-吡喃葡萄糖基)苯甲酸苯甲酯。
3.根据权利要求2所述的提取分离方法,其特征在于,所述步骤(1)中浓缩干燥的温度为40℃。
4.根据权利要求2所述的提取分离方法,其特征在于,步骤(2)中所述的乙酸乙酯萃取浸膏先用体积百分数为80%至90%的甲醇水溶液溶解,然后再上样。
5.一种组合物,其特征在于,该组合物包含权利要求1所述抗炎活性成分,以及药学可接受的载体或赋形剂。
6.权利要求1所述抗炎活性成分在制备抗炎药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810376906.1A CN108635361B (zh) | 2018-04-25 | 2018-04-25 | 一种具有抗炎活性的琼花提取物及其活性成分和分离方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810376906.1A CN108635361B (zh) | 2018-04-25 | 2018-04-25 | 一种具有抗炎活性的琼花提取物及其活性成分和分离方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108635361A CN108635361A (zh) | 2018-10-12 |
CN108635361B true CN108635361B (zh) | 2020-02-07 |
Family
ID=63747688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810376906.1A Active CN108635361B (zh) | 2018-04-25 | 2018-04-25 | 一种具有抗炎活性的琼花提取物及其活性成分和分离方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108635361B (zh) |
-
2018
- 2018-04-25 CN CN201810376906.1A patent/CN108635361B/zh active Active
Non-Patent Citations (1)
Title |
---|
Iridoid Glucosides from Viburnum macrocephalum;Lamberto Tomassini,etal;《Natural Product Communications》;20081231;第3卷(第6期);第845-846页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108635361A (zh) | 2018-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113754533B (zh) | 氧化半日花烷型二萜类化合物及其分离方法和应用 | |
CN111704544B (zh) | 一种半日花烷型二萜类化合物及其分离方法和应用 | |
CN115160337B (zh) | 1α-烷基瑞香烷型二萜类化合物及其制备方法和应用 | |
CN111253460B (zh) | 一种具有抗炎活性的三萜类药物及其制备方法和应用 | |
CN109824489A (zh) | 一种从甘草中提取的具有抗炎活性的化合物及其应用 | |
CN102659802A (zh) | 香豆素木脂体类化合物的制备方法及其抗海洋污损方面的应用 | |
CN110143991B (zh) | 单环单萜糖苷类化合物及其制备方法和用途 | |
CN108635361B (zh) | 一种具有抗炎活性的琼花提取物及其活性成分和分离方法 | |
CN111548327B (zh) | 降碳贝壳杉烷型二萜及其制备方法和在制备抗肿瘤药物中的用途 | |
CN108299368B (zh) | 黄酮类化合物及其制备方法与应用 | |
CN107722096B (zh) | 一种具有抗肿瘤作用的甾体类天然药物及其制备方法和用途 | |
CN112898357B (zh) | 金莲花中一种二萜苷类新化合物及其分离纯化方法和应用 | |
CN115521245A (zh) | 马齿苋中一种生物碱类化合物及其提取分离方法与应用 | |
CN113968869A (zh) | 愈创木烷倍半萜内酯类化合物Artemvulactone及其制备方法和应用 | |
CN112194704B (zh) | 一种甾体皂苷类化合物及其制备方法和应用 | |
CN111067924A (zh) | 一种具有抑制醛糖还原酶活性的琼花果实总木脂素提取物及其活性成分和用途 | |
CN104140391A (zh) | 一种从千金子中分离制备高纯度千金二萜醇二乙酸烟酸酯的方法 | |
CN109456163B (zh) | 一种具有对称结构的环烯酮类化合物及其制备方法和应用 | |
CN115558011B (zh) | 一种蒽酮类化合物及其制备方法和用途 | |
CN112920148B (zh) | 一种从牛蒡叶中提取的具有抗炎活性的新化合物nby-16及其制备方法与应用 | |
CN114106070B (zh) | 连翘中的二聚体环烯醚萜化合物及其提取分离方法和应用 | |
CN114853833B (zh) | 一种黄酮醇类衍生物及其制备方法 | |
CN116730957B (zh) | 一种乌药烷型倍半萜二聚体及其制备方法与应用 | |
CN112920146B (zh) | 倍半萜类化合物及其制备方法和在制备抗炎药物中的应用 | |
CN108299178B (zh) | 愈创木烷型倍半萜b及其制备方法和作为制备预防肿瘤和抗肿瘤药物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |